Adam's Take Adam's Take January 30, 2025 STAT Plus: MASH drugs reach a meaningful tipping point for patients and investors
Adam's Take Adam's Take January 23, 2025 STAT Plus: What to watch on Akero’s MASH-cirrhosis study results next month
Adam's Take Adam's Take January 16, 2025 STAT Plus: JPM Week rewind: M&A, mixed signals, and CEO chats
Adam's Take Adam's Take January 13, 2025 STAT Plus: Cytokinetics is not looking to be acquired, CEO says